Relacorilant Triplet with Bevacizumab Shows 59% Response Rate in Phase 2 Single-Arm Platinum-Resistant Ovarian Cancer Trial
A three-drug regimen involving relacorilant shrank tumors in 59% of 95 women with recurrent platinum-resistant ovarian cancer, though the early company-reported findings require further independent review.
Medical Daily ·